Production (Stage)
Kyverna Therapeutics, Inc.
KYTX
$3.39
$0.4515.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.64M | -37.49M | -34.49M | -28.80M | -26.69M |
| Total Depreciation and Amortization | 501.00K | 563.00K | 558.00K | 530.00K | 482.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.40M | -169.00K | 1.19M | -310.00K | 2.52M |
| Change in Net Operating Assets | -2.18M | 34.00K | 5.25M | 4.41M | -1.84M |
| Cash from Operations | -44.92M | -37.06M | -27.49M | -24.18M | -25.53M |
| Capital Expenditure | -- | -532.00K | -102.00K | -1.03M | -543.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.58M | 29.75M | 778.00K | -66.89M | -122.34M |
| Cash from Investing | 5.58M | 29.22M | 676.00K | -67.92M | -122.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -341.00K | -247.00K | -242.00K | -236.00K | -231.00K |
| Issuance of Common Stock | 3.00K | 32.00K | 90.00K | 73.00K | 341.24M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -76.00K | 0.00 | 0.00 | -406.00K | -2.96M |
| Cash from Financing | -414.00K | -215.00K | -152.00K | -569.00K | 338.05M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.75M | -8.05M | -26.97M | -92.67M | 189.65M |